Clinical trial
Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for…
NCT00487630 · Assistance Publique - Hôpitaux de Paris, Other · Unknown status
Key facts
| NCT number | NCT00487630 |
|---|---|
| Title | Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease |
| Official title | A Multicenter, Phase 4, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Recombinant Alpha-Galactosidase A (Agalsidase Beta, FABRAZYME) in Heterozygous Females for Fabry Disease |
| Acronym | HEART |
| Lead sponsor | Assistance Publique - Hôpitaux de Paris, Other |
| Status | Unknown status |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Fabry Disease |
| Intervention type | Drug |
| Interventions | recombinant alpha-galactosidase A |
| Enrollment | 34 |
| Start date | Jun 1, 2005 |
| Completion | Jun 1, 2009 |
| First posted | Jun 18, 2007 |
| Last update posted | Jun 18, 2007 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: